To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity,
PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects
with primary insomnia